Abrogation of the antibenzylpenicilloyl (BPO) IgE response with BPO-polyvinyl alcohol conjugates.
D000707:Anaphylaxis / Q000517:prevention & control; D000818:Animals; D004306:Dose-Response Relationship, Immunologic; D007108:Immune Tolerance; D007073:Immunoglobulin E / Q000096:biosynthesis*; D007165:Immunosuppression Therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D010047:Ovalbumin / Q000276:immunology; D010323:Passive Cutaneous Anaphylaxis; D010400:Penicillin G / Q000276:immunology* / Q000494:pharmacology / Q000627:therapeutic use; D011142:Polyvinyl Alcohol / Q000494:pharmacology* / Q000627:therapeutic use
D007073:Immunoglobulin E; D011142:Polyvinyl Alcohol; D010047:Ovalbumin; D010400:Penicillin G